Paraplegia following intrathecal cytosine arabinoside
Paraplegia following intrathecal cytosine arabinoside
复制标题
鞘内注射阿糖胞苷后截瘫
作者：
J. Zighelboim;R. Gale;L. Wolff
预防性内加性胞嘧啶阿拉伯糖苷（ARA -C）的截瘫患者在缓解剂中的急性骨髓性白血病患者中被描述为100 mg/m2/d，连续5天接受了100 mg/m2/d的剂量。单核性细胞增多症和蛋白质增加。在较长的间隔内以相同剂量的相同剂量给药，连续剂量之间的3-5天导致短暂的，短暂的神经系统符号（异常符号），只有30例被接受治疗的患者中的一名。
Paraplegia following prophylactic intrathecal cytosine arabinoside (Ara‐C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days. Cerebrospinal fluid examination prior to the last dosage of cytosine arabinoside revealed a mononuclear pleocytosis and increased protein. The neurological manifestations developed within one week after the last dose of Ara‐C and persisted for over 8 weeks. Administration of intrathecal Ara‐C in the same dose over longer intervals with 3‐5 days between consecutive doses resulted in mild, transient neurological symptoms (paresthesias) in only one of 30 patients so treated.